bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
174 hedge funds and large institutions have $303M invested in bluebird bio in 2022 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 54 increasing their positions, 45 reducing their positions, and 32 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 45
13% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 32
1% more funds holding
Funds holding: 172 → 174 (+2)
0.19% more ownership
Funds ownership: 4.15% → 4.34% (+0.19%)
48% less capital invested
Capital invested by funds: $581M → $303M (-$279M)
54% less call options, than puts
Call options by funds: $961K | Put options by funds: $2.09M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$36.5M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$10.2M |
| 3 |
Morgan Stanley
New York
|
+$7.16M |
| 4 |
Renaissance Technologies
New York
|
+$6.2M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$4.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$52M |
| 2 |
AC
Armistice Capital
New York
|
-$23.5M |
| 3 |
SC
Sessa Capital
New York
|
-$9.11M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.62M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$5.38M |
BLUE Hedge Fund Activity: Q1 2022 in Review
174 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2022, worth a combined $303M — down 48% from $581M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new BLUE positions and 32 closed out — a net gain of 4 holders — while 54 added to existing stakes and 45 trimmed.
The largest buyer was State Street, adding an estimated $36.5M. The largest seller was First Trust Advisors, exiting entirely with an estimated $52M sold.
- 174 institutional investors held bluebird bio (BLUE) as of Q1 2022, up from 172 in Q4 2021.
- Funds reported $303M of bluebird bio stock for Q1 2022, down 48% quarter-over-quarter.
- 36 funds opened new bluebird bio positions in Q1 2022 and 32 closed out, a net change of +4 holders.
- The largest bluebird bio buyer in Q1 2022 was State Street, an estimated $36.5M added.
- The largest bluebird bio seller in Q1 2022 was First Trust Advisors, an estimated $52M sold.
Based on aggregated 13F filings for Q1 2022.